💰 Veterinary medicines generate lower revenues than human equivalents, discouraging investment in pet treatments. 🐶🐱
💉 IgG monoclonal antibodies are costly to manufacture, limiting their availability for animal health. 🐾
🔒 Patents protect human treatments, making it difficult to transfer them to pets. 🚫
😺 A combination of VHH antibodies and QTL technology offers affordable therapeutics for pets, improving their quality of life. 🐾
🦙 VHH antibodies, found in camels, llamas, and alpacas, can replicate the therapeutic impacts of IgG monoclonal antibodies. 🧬
👩⚕️ QTL technology optimizes VHH manufacturing and lowers costs for pet therapeutics. 💲
🐶 Veterinary VHH therapeutics can reach the market quickly without breaching existing patents. 🚀
👨🔬 This innovative approach could revolutionize pet treatment and extend their lives. 🐾
Introduction:
The article discusses the lack of affordable and effective treatments for pets and the reasons behind it. It highlights the lower profits generated by veterinary medicines compared to human medicines, the high costs of manufacturing monoclonal antibodies, and the fierce protection of patents in the industry. However, the article introduces a new technology called QTL, which is applied to special antibody proteins called VHH. This technology offers hope for affordable therapeutics for pets by bypassing the obstacles faced by traditional monoclonal antibodies.
- Pets and humans have similar biology, but veterinary medicines generate lower revenues compared to human medicines, limiting investment in pet treatments.
- The high costs of manufacturing monoclonal antibodies make them commercially unviable for the price-sensitive animal health market.
- The fiercely guarded patent estates of monoclonal antibodies prevent their transfer to pets, further limiting treatment options for animals.
- QTL technology applied to VHH can create affordable therapeutics equivalent to monoclonal antibodies for pets.
- VHH, derived from camels, llamas, and alpacas, can replicate the therapeutic impacts of many monoclonal antibodies.
Conclusion:
The combination of VHH and QTL technology offers a promising solution to the lack of affordable therapeutics for pets. By bypassing the limitations of traditional monoclonal antibodies, VHH-based treatments can provide effective and cost-efficient solutions for pet owners, improving the quality of life for their beloved animals.
